Brokers Issue Forecasts for Gossamer Bio FY2024 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities research analysts at HC Wainwright lifted their FY2024 earnings per share estimates for shares of Gossamer Bio in a note issued to investors on Monday, November 11th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.18) per share for the year, up from their previous estimate of ($0.21). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2024 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.28 EPS.

Separately, Wedbush reaffirmed an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Trading Down 5.6 %

NASDAQ:GOSS opened at $0.77 on Wednesday. The stock has a market capitalization of $174.48 million, a price-to-earnings ratio of -2.42 and a beta of 1.96. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.60. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a 50 day moving average of $0.94 and a 200 day moving average of $0.86.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The firm had revenue of $9.48 million during the quarter, compared to the consensus estimate of $4.52 million.

Institutional Trading of Gossamer Bio

Several institutional investors and hedge funds have recently bought and sold shares of GOSS. SG Americas Securities LLC purchased a new position in shares of Gossamer Bio during the first quarter worth $34,000. Monaco Asset Management SAM lifted its holdings in shares of Gossamer Bio by 98.6% in the 1st quarter. Monaco Asset Management SAM now owns 556,000 shares of the company’s stock valued at $656,000 after buying an additional 276,000 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Gossamer Bio by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 11,763,784 shares of the company’s stock valued at $13,881,000 after buying an additional 128,150 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Gossamer Bio by 51.6% in the first quarter. Acadian Asset Management LLC now owns 2,736,385 shares of the company’s stock worth $3,227,000 after buying an additional 931,248 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its holdings in Gossamer Bio by 27.2% during the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock worth $84,000 after acquiring an additional 20,000 shares during the period. 81.23% of the stock is currently owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.